# A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)

> **NCT05035082** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 1020 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** semaglutide
- **DRUG:** oral glucose-lowering medications (commercially available)

## Key facts

- **NCT ID:** NCT05035082
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2025-06-18
- **Final completion:** 2025-06-18
- **Target enrollment:** 1020 (ACTUAL)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035082, "A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05035082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*